Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Last $1.75 USD
Change Today -0.02 / -1.13%
Volume 490.8K
CYTR On Other Exchanges
As of 8:10 PM 02/8/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

11726 San Vicente Boulevard

Suite 650

Los Angeles, CA 90049

United States

Phone: 310-826-5648

Fax: 310-826-6139

CytRx Corporation operates as a biopharmaceutical research and development company specializing in oncology. Aldoxorubicin The company focuses on the clinical development of aldoxorubicin (formerly known as INNO-206), its modified version of the widely-used chemotherapeutic agent, doxorubicin. In 2014, the company initiated a pivotal Phase 3 trial of aldoxorubicin as a therapy for patients with soft tissue sarcoma (STS) whose tumors have progressed following treatment with chemotherapy, and the company has received approval from the U.S. Food and Drug Administration (FDA) to continue dosing patients with aldoxorubicin until disease progression in that clinical trial. The Phase 3 trial is being conducted under a Special Protocol Assessment (SPA), granted by the FDA. The company is in the process of evaluating aldoxorubicin in a global Phase 2b clinical trial in small cell lung cancer, a Phase 2 clinical trial in HIV-related Kaposi's sarcoma, a Phase 2 clinical trial in patients with late-stage glioblastoma (brain cancer), a Phase 1b trial in combination with ifosfamide in patients with soft tissue sarcoma, and a Phase 1b trial in combination with gemcitabine in subjects with metastatic solid tumors. The company has completed a global Phase 2b clinical trial with aldoxorubicin as a first-line therapy for STS, a Phase 1b/2 clinical trial primarily in the same indication, a Phase 1b clinical trial of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors and a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. Research and Development The company’s expenditures for research and development activities related to continuing operations were $36.7 million, as of December 31, 2014. Intellectual Property Patents: As of March 9, 2015, the company held rights in 4 granted U.S. patents, 55 granted foreign patents, 1 pending U.S. application, 2 pending international applications (PCT), and 9 pending foreign patent applications covering aldoxorubicin and related technologies. The company’s intellectual property holdings relating to aldoxorubicin and related technologies include an exclusive license from KTB Tumorforschungs GmbH to U.S. and foreign patents and patent applications. Patents and applications that cover pharmaceutical compositions of aldoxorubicin, processes for their production, and their use in treatment methods have unextended patent terms expiring between June 2020 and June 2034. History CytRx Corporation, a Delaware corporation, was founded in 1985. The company was incorporated in 1985.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYTR:US $1.75 USD -0.02

CYTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYTR.
View Industry Companies

Industry Analysis


Industry Average

Valuation CYTR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1,130.1x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 468.7x

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact CYTRX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at